6 completed, 5 recruiting, 2 unknown, 1 active not recruiting. 15 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 15 | Completed 6, Recruiting 5, Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
Follow Paraneoplastic Syndromes: new trials by email Literature Review of Paraneoplastic Syndromes trials Research Report on Paraneoplastic Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome Osilodrostat, Placebo - Hypertension, Hypercortisolemia | Phase 4 | Recruiting | RECORDATI GROUP | 63 | 2026-08-26 | 2026-11-02 |
| IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion Intervention 1: Adrenalectomy, Intervention 2: Semaglutide - Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS) | Phase 4 | Recruiting | University of Texas Southwestern Medical Center | 75 | 2026-03-05 | 2026-11-18 |
| A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab Oral Corticosteroid Tapering Schedule, Ravulizumab, Prednisone/Prednisolone - Generalized Myasthenia Gravis, gMG | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 75 | 2026-03-04 | 2026-04-09 |
| Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS) Osilodrostat (Isturisa) - Mild Autonomous Cortisol Secretion (MACS) | Phase 4 | Recruiting | Johns Hopkins University | 10 | 2026-02-02 | 2026-10-23 |
| Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis Rozanolixizumab - Myasthenia Gravis | Phase 4 | Active not recruiting | UCB Biopharma SRL | 40 | 2025-12-01 | 2026-10-29 |
| Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod Efgartigimod - Myasthenia Gravis, Generalized | Phase 4 | Recruiting | Centre Hospitalier Universitaire de Nice | 50 | 2025-09-19 | 2026-09-03 |
| Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis Telitacicept - Myasthenia Gravis, Autoimmune Diseases | Phase 4 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 30 | 2024-12-01 | 2024-12-09 |
| Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis Pyridostigmine, Placebo oral capsule - Myasthenia Gravis | Phase 4 | Unknown | University of Aarhus | 44 | 2018-04-09 | 2018-04-27 |
| A Randomized Clinical Trial About Use of 3D Laparoscopy Versus 2D Laparoscopy in Adrenal Surgery laparoscopic adrenalectomy - Adrenal Mass, Adrenal Adenoma | Phase 4 | Completed | University of Palermo | 350 | 2018-01-01 | 2024-08-28 |
| Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Synacthen infusion during adrenal venous sampling - Primary Aldosteronism | Phase 4 | Unknown | Charles University, Czech Republic | 40 | 2011-03-01 | 2014-05-01 |
| Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Prednisone - Azathioprine - Myasthenia Gravis | Phase 4 | Completed | Assistance Publique - Hôpitaux de Paris | 118 | 2009-06-01 | 2017-10-13 |
| Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis IVIG, PLEX - Myasthenia Gravid | Phase 4 | Completed | University Health Network, Toronto | 87 | 2007-03-01 | 2010-08-11 |
| Treatment of Zollinger-Ellison Syndrome With Prevacid Lansoprazole (Prevacid) - Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia | Phase 4 | Completed | Charles Mel Wilcox, MD | 72 | 2003-03-01 | 2012-10-30 |
| A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) Mitoxantrone - Neuromyelitis Optica, Myelitis, Transverse | Phase 4 | Completed | State University of New York at Buffalo | 5 | 2001-08-01 | 2020-12-28 |
| Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis interferon beta 1a 30 ug IM once weekly - Multiple Sclerosis, Optic Neuritis | Phase 4 | Completed | Beth Israel Deaconess Medical Center | 155 | 2001-02-01 | 2017-09-06 |
Myasthenia Gravis (7) · ACTH Syndrome, Ectopic (5) · Hypertension (3) · Cushing Syndrome (2) · Myelitis, Transverse (2) · Adrenal Gland Neoplasms (1) · Adrenal Hyperplasia, Congenital (1) · Adrenal Insufficiency (1) · Adrenal incidentaloma (1) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Cerebellar Diseases (1) · Demyelinating Autoimmune Diseases, CNS (1) · Hyperaldosteronism (1) · Insulin Resistance (1)
Neoplasms (15) · Neoplasms by Site (11) · Immune System Diseases (9) · Nervous System Diseases (9) · Nervous System Neoplasms (9) · Neurodegenerative Diseases (9) · Paraneoplastic Syndromes, Nervous System (9) · Autoimmune Diseases (8) · Autoimmune Diseases of the Nervous System (8) · Endocrine System Diseases (7) · Neuromuscular Diseases (7) · Neuromuscular Junction Diseases (7) · Adrenal Gland Diseases (6) · Paraneoplastic Endocrine Syndromes (6)
Osilodrostat (2) · Prednisone (2) · Pyridostigmine Bromide (2) · Immunoglobulins, Intravenous (1) · Interferon beta-1a (1) · Lansoprazole (1) · Mitoxantrone (1) · Prednisolone (1) · efgartigimod alfa (1) · ravulizumab (1) · rozanolixizumab (1) · telitacicept (1)
Alexion Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Beth Israel Deaconess Medical Center (1) · Centre Hospitalier Universitaire de Nice (1) · Charles Mel Wilcox, MD (1) · Charles University, Czech Republic (1) · First Affiliated Hospital of Wenzhou Medical University (1) · Johns Hopkins University (1) · RECORDATI GROUP (1) · State University of New York at Buffalo (1) · UCB Biopharma SRL (1) · University Health Network, Toronto (1) · University of Aarhus (1) · University of Palermo (1) · University of Texas Southwestern Medical Center (1)
United States (6) · Canada (2) · France (2) · Italy (2) · China (1) · Czechia (1) · Denmark (1) · Germany (1) · Japan (1)
Amir Hamrahian, MD (1) · Bianca Weinstock-Guttman, M.D. (1) · C. Mel Wilcox, M.D. (1) · David Barth, MD (1) · Irina Bancos, MD (1) · Jan LS Thomsen, MD (1) · Jiri Ceral, MD (1) · Revere P Kinkel, MD (1) · Tarek Sharshar, MD PH (1) · Vera Bril, BSc, MD, FRCPC (1)
PMID 15645403, PMID 16831964, PMID 17767471, PMID 18507843, PMID 19581810, PMID 21073392, PMID 21193359, PMID 26708842, PMID 27454103, PMID 28887710, PMID 29510982, PMID 30817193, PMID 31206616, PMID 33555314, PMID 35220871, PMID 3536461, PMID 35817047, PMID 36952249, PMID 37318239, PMID 37801655, PMID 39062179, PMID 39086899, PMID 6135282
2025 (1), K23DK142038 (1)